Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: CD123 directed therapies - Deltagen

Drug Profile

Research programme: CD123 directed therapies - Deltagen

Alternative Names: Anti-leukaemia stem cell therapies research programme - Deltagen; CD123 targeted drugs research programme - Deltagen

Latest Information Update: 26 Apr 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Deltagen
  • Class Monoclonal antibodies; Small molecules
  • Mechanism of Action Interleukin 3 receptor alpha subunit modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia

Most Recent Events

  • 26 Apr 2007 Discontinued - Preclinical for Acute myeloid leukaemia in USA (unspecified route)
  • 01 Jul 2003 Deltagen has filed a voluntary petition under Chapter 11 of the federal Bankruptcy Code
  • 04 Sep 2002 Deltagen expects to file an IND in the first half of 2003 for an anti-CD123 monoclonal antibody.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top